Haloperidol Blood Levels and Clinical Effects

Archives of General Psychiatry

Volumn 49, Issue 5, 1992, Pages 354-361

  Volavka, Jan ^a,b,c   Cooper, Thomas ^a,b,d   Czobor, Pal ^a,b   Bitter, Istvan ^a,b,e   Meisner, Morris ^a,b   Laska, Eugene ^a,b   Gastanaga, Pedro ^a,b,c   Krakowski, Menahem ^a,b   Crowner, Martha ^a,b,c   Douyon, Richard ^b,c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c MANHATTAN PSYCHIATRIC CENTER   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA;

ACUTE DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HALOPERIDOL; HUMAN; PLACEBOS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026643073     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1992.01820050018002     Document Type: Article

References (51)

1. Baldessarini RJ, Cohen B, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988;45: 79–91.
2. Volavka J, Cooper TB. Review of haloperidol blood level and clinical response: looking through the window. J Clin Psychopharmacol. 1987;7: 25–30.
3. Extein I, Augusthy KA, Gold MS, Pottash AL, Martin D, Potter WZ. Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull. 1982;18: 156–158.
4. Miller DD, Hershey L, Duffy P, Abernethy DR, Greenblatt DJ. Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Pharmacol. 1984;4: 305–310.
5. Hollister LE, Kim DY. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Am J Psychiatry. 1982;139: 1466–1468.
6. Forsman A, Ohman R. Applied pharmacokinetics of haloperidol in man. Curr Ther Res. 1977;21: 396–411.
7. Magliozzi JR, Hollister LE, Arnold KV, Earle GM. Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry. 1981;138: 365–367.
8. Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R. Haloperidol plasma levels and critical response: basic concepts and clinical data. Psychopharmacol Bull. 1985;21: 48–51.
9. Rao RVA, Bishop M, Coppen A. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. Br J Psychiatry. 1980;137: 518–521.
10. De Buck RP, Zelaschi N, Gilles C, Durdu J, Brauman H. Theoretical and practical importance of plasma levels of haloperidol: correlations with clinical and computerized EEG data. Progr Neuropsychopharmacol. 1981;5: 499–502.
11. Tune LE. Haloperidol drug level monitoring: pharmacokinetic and methodologic considerations with special emphasis on radioreceptor assay techniques. In: Ayd FJ, ed. Haloperidol Update: 1958–1980. Baltimore, Md: Ayd Medical Communications; 1980: 220–230.
12. Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH, Waehrens J. High dosage haloperidol therapy in chronic schizophrenic patients: a double blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology. 1980;67: 17–23.
13. Balant-Gorgia HE, Eisele R, Balant L, Garrone G. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur Arch Psychiatr Neurol Sci. 1984;234: 1–4.
14. Moulin MA, Davy JP, Debruyne D, Anderson JC, Bigot MC, Camsonne R, Poilpre E. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients. Psychopharmacology. 1982;76: 346–350.
15. Neborsky R, Janowsky D, Munson R, Depry D. Rapid treatment of acute psychotic symptoms with high-and low-dose haloperidol. Arch Gen Psychiatry. 1981;38: 195–199.
16. Gerlach J, Behnre K, Heltberg J, Munk-Andersen E, Mielsen H. Sulpiride and haloperidol in schizophrenia: a double blind crossover study of therapeutic effect, side effects and plasma concentration. Br J Psychiatry. 1984;147: 283–288.
17. Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R. Does a therapeutic window for plasma haloperidol exist? preliminary Chinese data. Psychopharmacol Bull. 1985;21: 59–61.
18. Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, De John C. Haloperidol: plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical vs radioreceptor plasma level assays. Arch Gen Psychiatry. 1984;41: 1044–1049.
19. Van Putten T, Marder SR, May PRA, Poland E, O'Brien RP. Plasma level of haloperidol and clinical response. Psychopharmacol Bull. 1985;21: 69–72.
20. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology. 1981;81: 354–356.
21. Cohen BM, Baldessarini RJ. Haloperidol and clinical response. Am J Psychiatry. 1981;138: 1513–1514.
22. Wistedt B, Johanidesz G, Omerhodzic M, Arthur H, Bertilsson L, Petters I. Plasma haloperidol levels and clinical response in acute schizophrenia. Nord Psychiatr Tidsskr. 1984;1: 9–13.
23. Bigelow LB, Kirch DG, Braun T, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: fixed dose study. Psychopharmacol Bull. 1985;21: 66–68.
24. Bleeker JAC, Dingemans PM, Frohn-De Winter ML, van de Slooten EPJ. Plasma level and effect of low dose haloperidol in acute psychosis. Psychopharmacol Bull. 1984;20: 317–319.
25. Itoh H, Yagy G, Fujii Y, Iwamura K, Ichikawa K. The relationship between haloperidol blood levels and clinical responses. Progr Neuropsychopharmacol Biol Psychiatry. 1984;8: 285–292.
26. Linkowski P, Hubain P, von Frenckell R, Mendlewicz J. Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatr Neurol Sci. 1984;234: 231–236.
27. Rimon R, Averbuch I, Rozick P, Fijman-Danilovich L, Kara T, Dasberg H, Ebstein RP, Belmaker R. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology. 1981;73: 197–199.
28. Peck C. The randomized concentration-controlled clinical trial (CCT): an information-rich alternative to the randomized placebocontrolled trial (PCT). Clin Pharmacol Ther. 1990;47: 148–148.
29. Kragh-Sorensen P, Hansen C, Gaastrup T, Hvidberg E. Selfinhibiting action of nortryptiline to antidepressant effects at high plasma levels: a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression. Psychopharmacologia. 1976;45: 305–312.
30. Volavka J, Cooper TB, Meisner M, Bitter I, Czobor P, Jaeger J. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Psychopharmacol Bull. 1990;26: 13–17.
31. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35: 773–782.
32. Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry. 1978;35: 837–844.
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: National Institute of Mental Health; 1976.
34. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212(suppl): 9–11.
35. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Psychopharmacol Bull. 1988;24: 172–175.
36. Rifkin A, Doddi SR, Karajgi BM, Borenstein M, Wachspress M. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry. 1991;48: 166–170.
37. Bianchetti G, Morselli PL. Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorus selective detection. J Chromatogr. 1978;153: 203–209.
38. Thiemann S, Csernansky JG, Berger PA. Rating scales in research: the case of negative symptoms. Psychiatry Res. 1987;20: 47–55.
39. Laska EM, Siegel C, Sunshine A. Onset and duration: measurement and analysis. Clin Pharmacol Ther. 1991;49: 1–5.
40. Levinson DG, Simpson GM, Singh H, Cooper TB, Laska EV, Midha KK. Neuroleptic plasma level may predict response in patients who meet a criterion for improvement. Arch Gen Psychiatry. 1988;45: 878–879.
41. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J, Cooper T. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry. 1989;46: 482–483.
42. Coryell W, Kelly M, Perry PJ, Miller DD. Haloperidol plasma levels and acute clinical change in schizophrenia. J Clin Psychopharmacol. 1990;10: 397–402.
43. Smith RC. Plasma haloperidol levels and clinical response. Arch Gen Psychiatry. 1987;44: 1110–1112.
44. Miller F, Tanenbaum JH. Outcome of a low dose neuroleptic treatment strategy. J Clin Psychopharmacol. 1988;8: 378–379.
45. Neto MRL, Muller-Spahn F, Ruther E, Scherer J. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment on acute schizophrenic patients. Pharmacopsychiatry. 1988;21: 225–231.
46. Santos JL, Cabranes JA, Vasquez C, Fuentenebro F, Almoguera I, Ramos JA. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia. Biol Psychiatry. 1989;26: 381–388.
47. Wode-Helgodt B, Borg S, Fyro B, Sedvall G. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand. 1978;58: 149–173.
48. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40: 1113–1117.
49. Hubbard JW, Ganes D, Midha KK. Prolonged pharmacologic activity of neuroleptic drugs. Arch Gen Psychiatry. 1987;44: 99–100.
50. Cohen BM, Babb S, Campbell A, Baldessarini RJ. Persistence of haloperidol in the brain. Arch Gen Psychiatry. 1988;45: 879–880.
51. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45: 71–76.